Human leukocyte antigen-C (HLA-C) serum level as an indicator of severity among acute respiratory syndrome coronavirus patients
##plugins.themes.bootstrap3.article.main##
Abstract
One of the respiratory viruses with the highest rate of dissemination, the coronavirus, sparked a global pandemic that claimed the lives of roughly six million people. As a result, various vaccinations and medications to lessen disease severity and hasten patient recovery were developed quickly. The purpose of this study was for coronavirus patients with acute lung distress to have their serum levels measured and compared to healthy controls. One hundred eighty blood samples from respiratory infections syndrome coronavirus patients between the ages of (13-80) were included in this case-control research. Results showed that human leukocyte antigen-C (HLA-C) serum concentrations were measured in patient groups compared to healthy groups. Patients with acute lung symptoms of coronavirus had higher serum levels of HLA-C, and the outcomes were contrasted using the Kruskal-Wallis. Upon testing, it was discovered that their serum levels for HLA-C showed a significant difference (P< 0.05). There were▫severe corona patients without pneumonia having a level of 40.03 ng/ml, severe corona patients with pneumonia having a level of 47.93ng/ml, non-severe corona patients without pneumonia having a level of 46.83 ng/ml, non-severe corona patients with pneumonia cases having a level of 61.15 ng/ml and with controls having a level of 17.65 ng/ml, (P ≤0.001). An increase in HLA-C serum level led to contribute to the immune storm that changes immunoregulatory▫such as including reducing the number ofˑallogeneic made by mixing lymphocyteˌcultures, death of the natural killer cell and CD8+ˌT lymphocytes, and inhibition of alloreactive cytotoxic T lymphocytes (CTL) activity.
##plugins.themes.bootstrap3.article.details##
##plugins.themes.bootstrap3.article.details##
Acute respiratory syndrome coronavirus, ELSA test, Human leukocyte antigen (HLA-C), Pneumonia
Al-Bayatee, N. T. & Ad’hiah, A. H. (2021). Soluble HLA-G is upregulated in the serum of patients with severe COVID-19. Human Immunology, 82(10), 726–732. https://doi.org/10.1016/j.humimm.2021.07.007
Bian, Q & Fu, B. (2022). Immunological microenvironment at the maternal-fetal interface. Journal of Reproductive Immunology, 151, 103632. https://doi.org/10.1016/j.jri.202 2.103632
Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C., & Melguizo-Rodríguez, L. (2020). SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine and Growth Factor Reviews, 54, 62–75. https://doi.org/10.1016/j.cytogfr.2020.06.001
De Wit, J., Borghans, J. A., Kesmir, C. & Van Baarle, D. (2016) [Editorial]. Role of HLA and KIR in viral infections. Frontiers in Immunology, 7, 286. https://doi.org/10.3389/fimmu.2016.00286
Hansen, T. H., & Bouvier, M. (2009). MHC class I antigen presentation: Learning from viral evasion strategies. Nature Reviews. Immunology, 9(7), 503–513. https://doi.org/10.1038/nri2575
Hosseini, A., Hashemi, V., Shomali, N., Asghari, F., Gharibi, T., Akbari, M., Gholizadeh, S. & Jafari, A. (2020). Innate and adaptive immune responses against coronavirus. Biomedicine and Pharmacotherapy, 132, 110859. https://doi.org/10.1016/j.biopha.202 0.110 859
Imrie, A. & McCarthy, S. (2021). HLA and immunodominance in viral infection: T-cell responses in protection and immunopathogenesis. Microbiology Australia, 42(2), 84–86. https://doi.org/10.1071/MA21020
Josset, L., V. D. Menachery, G., L. E., Agnihothram, S., Sova, P., Carter, V. S., Yount, B. L., Graham, R. L., Baric, R. S. & Katze, M. G. (2013). Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio, 4(3), e00165–e00113. https://doi.org/10.1128/mBio.00165-13.
Kubysheva, N., Soodaeva, S., Novikov, V., Eliseeva, T., Li, T., Klimanov, I., Kuzmina, E., Baez-Medina, H., Solovyev, V., Ovsyannikov, D. Y. & Batyrshin, I. (2018). Soluble HLA-I and HLA-II molecules are potential prognostic markers of the progression of systemic and local inflammation in patients with COPD. Disease Markers, 2018, 3614341. https://doi.org/10.1155/2018/3614341
Lin, A. & Yan, W. H. (2021). Perspective of HLA-G induced immunosuppression in SARS-CoV-2 infection. Frontiers in Immunology, 12, 788769. https://doi.org/10.3389/fimmu.2021.788769
Meuleman, T., Haasnoot, G. W., van Lith, J. M. M., Verduijn, W., Bloemenkamp, K. W. M., & Claas, F. H. J. (2018). Paternal HLA‐C is a risk factor in unexplained recurrent miscarriage. American Journal of Reproductive Immunology, 79(2), e12797. https://doi.org/10.1111/aji.12797
Nelde, A., Rieth, J., Roerden, M., Dubbelaar, M. L., Hoenisch Gravel, N. H., Bauer, J., Klein, R., Hoheisel, T., Mahrhofer, H., Göpel, S., Bitzer, M., Hörber, S., Peter, A., Heitmann, J. S. & Walz, J. S. (2022). Increased soluble HLA in COVID-19 presents a disease-related, diverse immunopeptidome associated with T cell immunity. iScience, 25(12), 105643. https://doi.org/10.1016/j.isci.202 2.105643
Saulle, I., Vicentini, C., Clerici, M. & Biasin, M. (2021). Antigen presentation in SARS-CoV-2 infection: The role of class I HLA and ERAP polymorphisms. Human Immunology, 82(8), 551–560. https://doi.org/10.1016/j.humimm.202 1.05.003
Tahaghoghi-Hajghorbani, S., Zafari, P., Masoumi, E., Rajabinejad, M., Jafari-Shakib, R., Hasani, B. & Rafiei, A. (2020). The role of dysregulated immune responses in COVID-19 pathogenesis. Virus Research, 290, 198197. https://doi.org/10.1016/j.virusres.2020.198197
Trowsdale, J. & Knight, J. C. (2013). Major histocompatibility complex genomics and human disease. Annual Review of Genomics and Human Genetics, 14, 301–323. https://doi.org/10.1146/annurev-genom-091212-153455
Vollmers, S., Lobermeyer, A. & Körner, C. (2021). The new kid on the block: HLA-C, a key regulator of natural killer cells in viral immunity. Cells, 10(11), 3108. https://doi.org/10.3390/cells10113108
Wang, C., Wang, Z., Wang, G., Lau, J. Y. N., Zhang, K., & Li, W. (2021). COVID-19 in early 2021: Current status and looking forward. Signal Transduction and Targeted Therapy, 6(1), 114. https://doi.org/10.1038/s41392-021-00527-1
Wyatt, R. C., Lanzoni, G., Russell, M. A., Gerling, I. & Richardson, S. J. (2019). What the HLA-I!—Classical and nonclassical HLA class I and their potential roles in type 1 diabetes. Current Diabetes Reports, 19(12), 1–11. https://doi.org/10.1007/s11892-019-1245-z
Zhang, L., Li, R., Song, G., Scholes, G. D. & She, Z. S. (2021). Impairment of T cells’ antiviral and anti-inflammation immunities may be critical to death from COVID 19. Royal Society Open Science, 8(12), 211606. https://doi.org/10.1098/rsos.211606.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) © Author (s)
